Compare SPDR Gold Trust (GLD) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs Illumina, Inc. — how do they compare? SPDR Gold Trust trades at $365.6, while Illumina, Inc. trades at $189.47 (market cap $28.32B). The key difference: Illumina, Inc. is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.
| GLD | ILMN | |
|---|---|---|
52-Week High | $495.90 | $194.33 |
52-Week Low | $300.96 | $91.00 |
Market Cap | — | $28.32B |
Sector | — | Health |
Enterprise Value | — | $29.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD (SPDR Gold Shares ETF) trades at $365.75, down 1.72% amid bearish technical signals with 14 sell indicators. The ETF tracks physical gold prices, currently facing pressure from stabilizing dollar and rate-hike expectations. Recent economic data shows mixed signals with cooling inflation but strong labor market data weighing on gold prices. The fund provides direct exposure to gold bullion with lower volatility compared to mining stocks.
Gold's near-term outlook faces headwinds from potential Fed rate policy and dollar strength, though geopolitical tensions and central bank accumulation provide support. The technical picture suggests consolidation near key support levels with bearish momentum indicators. Investors should monitor Fed policy signals and inflation data for directional catalysts.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
